254 related articles for article (PubMed ID: 6230409)
1. Objective assessment of heparin requirements for hemodialysis in humans.
Ireland H; Lane DA; Curtis JR
J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
[TBL] [Abstract][Full Text] [Related]
2. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
[TBL] [Abstract][Full Text] [Related]
3. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
4. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin.
Gallino A; Haeberli A; Hess T; Mombelli G; Straub PW
Am Heart J; 1986 Aug; 112(2):285-90. PubMed ID: 2426934
[TBL] [Abstract][Full Text] [Related]
5. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
[TBL] [Abstract][Full Text] [Related]
6. The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.
Gunnarsson B; Asaba H; Dawidson S; Wilhelmsson S; Bergström J
Clin Nephrol; 1981 Mar; 15(3):135-42. PubMed ID: 7273488
[TBL] [Abstract][Full Text] [Related]
7. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
8. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
Murakoshi T
Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
[TBL] [Abstract][Full Text] [Related]
9. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation.
Nichols AB; Owen J; Grossman BA; Marcella JJ; Fleisher LN; Lee MM
Circulation; 1984 Nov; 70(5):843-50. PubMed ID: 6237807
[TBL] [Abstract][Full Text] [Related]
10. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
[TBL] [Abstract][Full Text] [Related]
11. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
[TBL] [Abstract][Full Text] [Related]
12. Platelet factor 4 release induced by intravenous administration of heparin.
Cella G; Scattolo N; Cappellato MG; Girolami A; Strauss WE; Sasahara AA
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):165-74. PubMed ID: 2581862
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis.
Clyne N; Lins LE; Egberg N
Clin Nephrol; 1995 Apr; 43(4):260-7. PubMed ID: 7606881
[TBL] [Abstract][Full Text] [Related]
14. Platelet factor release following heparin administration and during extracorporeal circulation.
Flicker W; Milthorpe BK; Schindhelm K; Odell RA; McPherson J; Farrell PC
Trans Am Soc Artif Intern Organs; 1982; 28():431-6. PubMed ID: 6219490
[No Abstract] [Full Text] [Related]
15. Heparin is unable to prevent contact activation by three different membranes.
Stratta P; Canavese C; Mangiarotti G; Pacitti A; Tetta C; Coppo R; Ragni R; Vercellone A
Proc Eur Dial Transplant Assoc; 1981; 18():269-74. PubMed ID: 6460241
[TBL] [Abstract][Full Text] [Related]
16. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
17. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure.
Guzzo J; Niewiarowski S; Musial J; Bastl C; Grossman RA; Rao AK; Berman I; Paul D
J Lab Clin Med; 1980 Jul; 96(1):102-13. PubMed ID: 6446588
[TBL] [Abstract][Full Text] [Related]
18. Detection of enhanced in vivo platelet alpha-granule release in different patient groups--comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays.
Lane DA; Ireland H; Wolff S; Ranasinghe E; Dawes J
Thromb Haemost; 1984 Oct; 52(2):183-7. PubMed ID: 6084323
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR
Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924
[TBL] [Abstract][Full Text] [Related]
20. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?
Gritters M; Borgdorff P; Grooteman MP; Schoorl M; Schoorl M; Bartels PC; Tangelder GJ; Nubé MJ
Nephrol Dial Transplant; 2008 Sep; 23(9):2911-7. PubMed ID: 18364368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
